- Motley Fool•19 hours ago
Slowing sales growth for its rare-disease drugs kept the market second-guessing the biotech's potential.
- Zacks•6 days ago
Merck (MKGAF) and Vertex (VRTX) collaborated for the development and commercialization of four research and development programs for the treatment of cancer.
- Capital Cube•7 days ago
Categories: Fundamental Analysis Yahoo Finance Click here to see latest analysis Capitalcube gives Vertex Pharmaceuticals, Inc. a score of 28. Our analysis is based on comparing Vertex Pharmaceuticals, Inc. with the following peers – Gilead Sciences, Inc., AbbVie, Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Enzon Pharmaceuticals, Inc., Enanta Pharmaceuticals, Inc. and SciClone Pharmaceuticals, Inc. (GILD-US, ... Read more (Read more...)
VRTX : Summary for Vertex Pharmaceuticals Incorpor - Yahoo Finance
Vertex Pharmaceuticals Incorporated (VRTX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Day's Range||79.78 - 82.54|
|52 Week Range||71.46 - 103.73|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-71.91|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|